Dyadic International CEO Mark Emalfarb and Chief Business Officer Joe Hazelton joined Steve Darling from Proactive to share news the company has announced a major milestone with the company starting to dose patients in its Phase 1 clinical trial of DYAI-100 COVID-19 recombinant protein receptor binding domain booster vaccine candidate Emalfarb telling Proactive this trial is to test clinical safety and antibody response in humans and the results are expected to accelerate the adoption of the C-1 protein production platform for both vaccine and therapeutic candidates. Hazelton talks more about the process and where the trial is taking place.
Dyadic International starts dosing in Phase 1 clinical trial DYAI-100 booster vaccine candidate
